Papay R, Stauffer S, Perez D
Curr Res Pharmacol Drug Discov. 2023; 5:100160.
PMID: 37448695
PMC: 10336260.
DOI: 10.1016/j.crphar.2023.100160.
Lancini E, Haag L, Bartl F, Ruhling M, Ashton N, Zetterberg H
Brain Commun. 2023; 5(3):fcad085.
PMID: 37151227
PMC: 10154713.
DOI: 10.1093/braincomms/fcad085.
Sala A, Caminiti S, Presotto L, Pilotto A, Liguori C, Chiaravalloti A
Alzheimers Res Ther. 2021; 13(1):187.
PMID: 34772450
PMC: 8588696.
DOI: 10.1186/s13195-021-00925-1.
Ichinose T, Murasawa H, Ishijima T, Okada S, Abe K, Matsumoto S
PLoS One. 2020; 15(5):e0232233.
PMID: 32365077
PMC: 7197849.
DOI: 10.1371/journal.pone.0232233.
Chang H, Chang Y, Tsai S, Huang C, Hsu S, Liu M
Mol Neurobiol. 2018; 56(6):4518-4529.
PMID: 30338484
DOI: 10.1007/s12035-018-1394-0.
Complex noradrenergic dysfunction in Alzheimer's disease: Low norepinephrine input is not always to blame.
Gannon M, Wang Q
Brain Res. 2018; 1702:12-16.
PMID: 29307592
PMC: 6855395.
DOI: 10.1016/j.brainres.2018.01.001.
The Locus Coeruleus: Essential for Maintaining Cognitive Function and the Aging Brain.
Mather M, Harley C
Trends Cogn Sci. 2016; 20(3):214-226.
PMID: 26895736
PMC: 4761411.
DOI: 10.1016/j.tics.2016.01.001.
Mitochondrial function in ageing: coordination with signalling and transcriptional pathways.
Yin F, Sancheti H, Liu Z, Cadenas E
J Physiol. 2015; 594(8):2025-42.
PMID: 26293414
PMC: 4933098.
DOI: 10.1113/JP270541.
Hypermetabolic state in the 7-month-old triple transgenic mouse model of Alzheimer's disease and the effect of lipoic acid: a 13C-NMR study.
Sancheti H, Patil I, Kanamori K, Brinton R, Zhang W, Lin A
J Cereb Blood Flow Metab. 2014; 34(11):1749-60.
PMID: 25099753
PMC: 4269751.
DOI: 10.1038/jcbfm.2014.137.
Development of amyloid burden in African Green monkeys.
Kalinin S, Willard S, Shively C, Kaplan J, Register T, Jorgensen M
Neurobiol Aging. 2013; 34(10):2361-9.
PMID: 23601810
PMC: 3706498.
DOI: 10.1016/j.neurobiolaging.2013.03.023.
Bupropion and Citalopram in the APP23 Mouse Model of Alzheimer's Disease: A Study in a Dry-Land Maze.
Neumeister K, Riepe M
Int J Alzheimers Dis. 2012; 2012:673584.
PMID: 23056993
PMC: 3465969.
DOI: 10.1155/2012/673584.
Differential response of the central noradrenergic nervous system to the loss of locus coeruleus neurons in Parkinson's disease and Alzheimer's disease.
McMillan P, White S, Franklin A, Greenup J, Leverenz J, Raskind M
Brain Res. 2010; 1373:240-52.
PMID: 21147074
PMC: 3038670.
DOI: 10.1016/j.brainres.2010.12.015.
The dopamine β-hydroxylase -1021C/T polymorphism is associated with the risk of Alzheimer's disease in the Epistasis Project.
Combarros O, Warden D, Hammond N, Cortina-Borja M, Belbin O, Lehmann M
BMC Med Genet. 2010; 11:162.
PMID: 21070631
PMC: 2994840.
DOI: 10.1186/1471-2350-11-162.
Effect of a serotonin reuptake inhibitor on irritability, apathy, and psychotic symptoms in patients with Alzheimer's disease.
Siddique H, Hynan L, Weiner M
J Clin Psychiatry. 2009; 70(6):915-8.
PMID: 19422762
PMC: 3236068.
DOI: 10.4088/JCP.08m04828.
Changes in adrenoreceptors in the prefrontal cortex of subjects with dementia: evidence of compensatory changes.
Szot P, White S, Greenup J, Leverenz J, Peskind E, Raskind M
Neuroscience. 2007; 146(1):471-80.
PMID: 17324522
PMC: 3399726.
DOI: 10.1016/j.neuroscience.2007.01.031.
Adrenergic pharmacology and cognition: focus on the prefrontal cortex.
Ramos B, Arnsten A
Pharmacol Ther. 2007; 113(3):523-36.
PMID: 17303246
PMC: 2151919.
DOI: 10.1016/j.pharmthera.2006.11.006.
Reduction in CHT1-mediated choline uptake in primary neurons from presenilin-1 M146V mutant knock-in mice.
Payette D, Xie J, Guo Q
Brain Res. 2007; 1135(1):12-21.
PMID: 17196556
PMC: 1805819.
DOI: 10.1016/j.brainres.2006.12.005.
Compensatory changes in the noradrenergic nervous system in the locus ceruleus and hippocampus of postmortem subjects with Alzheimer's disease and dementia with Lewy bodies.
Szot P, White S, Greenup J, Leverenz J, Peskind E, Raskind M
J Neurosci. 2006; 26(2):467-78.
PMID: 16407544
PMC: 6674412.
DOI: 10.1523/JNEUROSCI.4265-05.2006.
Perspectives on MAO-B in aging and neurological disease: where do we go from here?.
Kumar M, Andersen J
Mol Neurobiol. 2004; 30(1):77-89.
PMID: 15247489
DOI: 10.1385/MN:30:1:077.
CHF2819: pharmacological profile of a novel acetylcholinesterase inhibitor.
Trabace L, Cassano T, Loverre A, Steardo L, Cuomo V
CNS Drug Rev. 2002; 8(1):53-69.
PMID: 12070526
PMC: 6741681.
DOI: 10.1111/j.1527-3458.2002.tb00215.x.